{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:07:28Z","timestamp":1792483648703,"version":"4.5.0"},"reference-count":239,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"United States Department of Defense","doi-asserted-by":"publisher","award":["KC200096P1"],"award-info":[{"award-number":["KC200096P1"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"United States Department of Defense","doi-asserted-by":"publisher","award":["Advanced Discovery Award"],"award-info":[{"award-number":["Advanced Discovery Award"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"United States Department of Defense","doi-asserted-by":"publisher","award":["Research award"],"award-info":[{"award-number":["Research award"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"United States Department of Defense","doi-asserted-by":"publisher","award":["Translational Research Award"],"award-info":[{"award-number":["Translational Research Award"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"United States Department of Defense","doi-asserted-by":"publisher","award":["1R01CA261978"],"award-info":[{"award-number":["1R01CA261978"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"United States Department of Defense","doi-asserted-by":"publisher","award":["5 P30 CA016672"],"award-info":[{"award-number":["5 P30 CA016672"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","award":["KC200096P1"],"award-info":[{"award-number":["KC200096P1"]}],"id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","award":["Advanced Discovery Award"],"award-info":[{"award-number":["Advanced Discovery Award"]}],"id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","award":["Research award"],"award-info":[{"award-number":["Research award"]}],"id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","award":["Translational Research Award"],"award-info":[{"award-number":["Translational Research Award"]}],"id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","award":["1R01CA261978"],"award-info":[{"award-number":["1R01CA261978"]}],"id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100003064","name":"Kidney Cancer Association","doi-asserted-by":"publisher","award":["5 P30 CA016672"],"award-info":[{"award-number":["5 P30 CA016672"]}],"id":[{"id":"10.13039\/100003064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["KC200096P1"],"award-info":[{"award-number":["KC200096P1"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["Advanced Discovery Award"],"award-info":[{"award-number":["Advanced Discovery Award"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["Research award"],"award-info":[{"award-number":["Research award"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["Translational Research Award"],"award-info":[{"award-number":["Translational Research Award"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["1R01CA261978"],"award-info":[{"award-number":["1R01CA261978"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001634","name":"Gateway for Cancer Research","doi-asserted-by":"publisher","award":["5 P30 CA016672"],"award-info":[{"award-number":["5 P30 CA016672"]}],"id":[{"id":"10.13039\/100001634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","award":["KC200096P1"],"award-info":[{"award-number":["KC200096P1"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","award":["Advanced Discovery Award"],"award-info":[{"award-number":["Advanced Discovery Award"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","award":["Research award"],"award-info":[{"award-number":["Research award"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","award":["Translational Research Award"],"award-info":[{"award-number":["Translational Research Award"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","award":["1R01CA261978"],"award-info":[{"award-number":["1R01CA261978"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001368","name":"V Foundation","doi-asserted-by":"publisher","award":["5 P30 CA016672"],"award-info":[{"award-number":["5 P30 CA016672"]}],"id":[{"id":"10.13039\/100001368","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH\/NCI R01","award":["KC200096P1"],"award-info":[{"award-number":["KC200096P1"]}]},{"name":"NIH\/NCI R01","award":["Advanced Discovery Award"],"award-info":[{"award-number":["Advanced Discovery Award"]}]},{"name":"NIH\/NCI R01","award":["Research award"],"award-info":[{"award-number":["Research award"]}]},{"name":"NIH\/NCI R01","award":["Translational Research Award"],"award-info":[{"award-number":["Translational Research Award"]}]},{"name":"NIH\/NCI R01","award":["1R01CA261978"],"award-info":[{"award-number":["1R01CA261978"]}]},{"name":"NIH\/NCI R01","award":["5 P30 CA016672"],"award-info":[{"award-number":["5 P30 CA016672"]}]},{"DOI":"10.13039\/100000054","name":"Cancer Center","doi-asserted-by":"publisher","award":["KC200096P1"],"award-info":[{"award-number":["KC200096P1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"Cancer Center","doi-asserted-by":"publisher","award":["Advanced Discovery Award"],"award-info":[{"award-number":["Advanced Discovery Award"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"Cancer Center","doi-asserted-by":"publisher","award":["Research award"],"award-info":[{"award-number":["Research award"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"Cancer Center","doi-asserted-by":"publisher","award":["Translational Research Award"],"award-info":[{"award-number":["Translational Research Award"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"Cancer Center","doi-asserted-by":"publisher","award":["1R01CA261978"],"award-info":[{"award-number":["1R01CA261978"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"Cancer Center","doi-asserted-by":"publisher","award":["5 P30 CA016672"],"award-info":[{"award-number":["5 P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>This article describes rationales and limitations for making inferences based on data from randomized controlled trials (RCTs). We argue that obtaining a representative random sample from a patient population is impossible for a clinical trial because patients are accrued sequentially over time and thus comprise a convenience sample, subject only to protocol entry criteria. Consequently, the trial\u2019s sample is unlikely to represent a definable patient population. We use causal diagrams to illustrate the difference between random allocation of interventions within a clinical trial sample and true simple or stratified random sampling, as executed in surveys. We argue that group-specific statistics, such as a median survival time estimate for a treatment arm in an RCT, have limited meaning as estimates of larger patient population parameters. In contrast, random allocation between interventions facilitates comparative causal inferences about between-treatment effects, such as hazard ratios or differences between probabilities of response. Comparative inferences also require the assumption of transportability from a clinical trial\u2019s convenience sample to a targeted patient population. We focus on the consequences and limitations of randomization procedures in order to clarify the distinctions between pairs of complementary concepts of fundamental importance to data science and RCT interpretation. These include internal and external validity, generalizability and transportability, uncertainty and variability, representativeness and inclusiveness, blocking and stratification, relevance and robustness, forward and reverse causal inference, intention to treat and per protocol analyses, and potential outcomes and counterfactuals.<\/jats:p>","DOI":"10.3390\/cancers15194674","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T03:44:42Z","timestamp":1695354282000},"page":"4674","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Interpreting Randomized Controlled Trials"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6505-8308","authenticated-orcid":false,"given":"Pavlos","family":"Msaouel","sequence":"first","affiliation":[{"name":"Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"},{"name":"Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"},{"name":"David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9787-3830","authenticated-orcid":false,"given":"Juhee","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of California Santa Cruz, Santa Cruz, CA 95064, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Thall","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Msaouel, P., Lee, J., and Thall, P.F. (2021). Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes. Cancers, 13.","DOI":"10.3390\/cancers13112741"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Msaouel, P., Lee, J., Karam, J.A., and Thall, P.F. (2022). A Causal Framework for Making Individualized Treatment Decisions in Oncology. Cancers, 14.","DOI":"10.3390\/cancers14163923"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1111\/rssc.12582","article-title":"Utility-based Bayesian personalized treatment selection for advanced breast cancer","volume":"71","author":"Lee","year":"2022","journal-title":"J. R. Stat. Soc. Ser. C Appl. Stat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1111\/biom.13738","article-title":"Bayesian treatment screening and selection using subgroup-specific utilities of response and toxicity","volume":"79","author":"Lee","year":"2022","journal-title":"Biometrics"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1093\/jamia\/ocaa163","article-title":"Trialstreamer: A living, automatically updated database of clinical trial reports","volume":"27","author":"Marshall","year":"2020","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2307\/1403151","article-title":"Representative sampling, IV: The history of the concept in statistics, 1895\u20131939","volume":"48","author":"Kruskal","year":"1980","journal-title":"Int. Stat. Rev.\/Rev. Int. De Stat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2307\/1402647","article-title":"Representative sampling, III: The current statistical literature","volume":"48","author":"Kruskal","year":"1979","journal-title":"Int. Stat. Rev.\/Rev. Int. De Stat."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Senn, S. (2021). Statistical Issues in Drug Development, John Wiley and Sons, Ltd.. [3rd ed.].","DOI":"10.1002\/9781119238614"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10654-017-0230-6","article-title":"For and Against Methodologies: Some Perspectives on Recent Causal and Statistical Inference Debates","volume":"32","author":"Greenland","year":"2017","journal-title":"Eur. J. Epidemiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/ppe.12711","article-title":"Analysis goals, error-cost sensitivity, and analysis hacking: Essential considerations in hypothesis testing and multiple comparisons","volume":"35","author":"Greenland","year":"2021","journal-title":"Paediatr. Perinat. Epidemiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107127","DOI":"10.1016\/j.ypmed.2022.107127","article-title":"To curb research misreporting, replace significance and confidence by compatibility: A Preventive Medicine Golden Jubilee article","volume":"164","author":"Greenland","year":"2022","journal-title":"Prev. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Rafi, Z., and Greenland, S. (2020). Semantic and cognitive tools to aid statistical science: Replace confidence and significance by compatibility and surprise. BMC Med. Res. Methodol., 20.","DOI":"10.1186\/s12874-020-01105-9"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/bmj.1.3923.554-a","article-title":"Design of experiments","volume":"1","author":"Fisher","year":"1936","journal-title":"Br. Med. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/ije\/dyg286","article-title":"Fisher, Bradford Hill, and randomization","volume":"32","author":"Armitage","year":"2003","journal-title":"Int. J. Epidemiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2307\/2532438","article-title":"RA Fisher and Experimental Design: A Review","volume":"46","author":"Preece","year":"1990","journal-title":"Biometrics"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1093\/ije\/dyg288","article-title":"Rigorous uncertainty: Why RA Fisher is important","volume":"32","author":"Marks","year":"2003","journal-title":"Int. J. Epidemiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1146\/annurev-statistics-040220-015348","article-title":"Six Statistical Senses","volume":"10","author":"Craiu","year":"2023","journal-title":"Annu. Rev. Stat. Its Appl."},{"key":"ref_18","unstructured":"Efron, B. (2005). Modern Science and the Bayesian-Frequentist Controversy, Division of Biostatistics, Stanford University."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Thall, P.F. (2019). Statistical Remedies for Medical Researchers, Springer International Publishing.","DOI":"10.1007\/978-3-030-29149-5"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Gelman, A., Simpson, D., and Betancourt, M. (2017). The Prior Can Often Only Be Understood in the Context of the Likelihood. Entropy, 19.","DOI":"10.3390\/e19100555"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gelman, A., Carlin, J.B., Stern, H.S., Dunson, D.B., Vehtari, A., and Rubin, D.B. (2013). Bayesian Data Analysis, Taylor & Francis. [3rd ed.].","DOI":"10.1201\/b16018"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clgc.2018.09.005","article-title":"Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients with Renal Medullary Carcinoma","volume":"17","author":"Msaouel","year":"2019","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ccell.2020.04.002","article-title":"Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma","volume":"37","author":"Msaouel","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wiele, A.J., Surasi, D.S., Rao, P., Sircar, K., Su, X., Bathala, T.K., Shah, A.Y., Jonasch, E., Cataldo, V.D., and Genovese, G. (2021). Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13092170"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1016\/j.clgc.2021.08.007","article-title":"Efficacy and safety of gemcitabine plus doxorubicin in patients with renal medullary carcinoma","volume":"19","author":"Wilson","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07357907.2022.2137914","article-title":"Risk Model Development and Validation in Clinical Oncology: Lessons Learned","volume":"41","author":"Lyman","year":"2023","journal-title":"Cancer Investig."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hansson, S.O., and Hendricks, V. (2018). Introduction to Formal Philosophy, Springer.","DOI":"10.1007\/978-3-319-77434-3"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1086\/286432","article-title":"Testability and Meaning","volume":"3","author":"Carnap","year":"1936","journal-title":"Philos. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/1740-9713.01587","article-title":"Addressing exaggeration of effects from single RCTs","volume":"18","author":"Schwab","year":"2021","journal-title":"Significance"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1002\/sim.9173","article-title":"The statistical properties of RCTs and a proposal for shrinkage","volume":"40","author":"Schwab","year":"2021","journal-title":"Stat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/stan.12241","article-title":"The significance filter, the winner\u2019s curse and the need to shrink","volume":"75","author":"Cator","year":"2021","journal-title":"Stat. Neerl."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00001648-199805000-00018","article-title":"Probability logic and probabilistic induction","volume":"9","author":"Greenland","year":"1998","journal-title":"Epidemiology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/ije\/27.4.543","article-title":"Induction versus Popper: Substance versus semantics","volume":"27","author":"Greenland","year":"1998","journal-title":"Int. J. Epidemiol."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Popper, K.R. (1963). Conjectures and Refutations: The Growth of Scientific Knowledge, Routledge and Kegan Paul.","DOI":"10.1063\/1.3050617"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10654-016-0149-3","article-title":"Statistical tests, P values, confidence intervals, and power: A guide to misinterpretations","volume":"31","author":"Greenland","year":"2016","journal-title":"Eur. J. Epidemiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/sjos.12625","article-title":"Divergence vs. Decision P-values: A Distinction Worth Making in Theory and Keeping in Practice\u2014Or, How Divergence P-values Measure Evidence Even When Decision P-values Do Not","volume":"50","author":"Greenland","year":"2023","journal-title":"Scand. J. Stat."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/aje\/kwaa136","article-title":"Surprise!","volume":"190","author":"Cole","year":"2021","journal-title":"Am. J. Epidemiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/01621459.2017.1289846","article-title":"Statistical Significance and the Dichotomization of Evidence","volume":"112","author":"McShane","year":"2017","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/d41586-019-00857-9","article-title":"Scientists rise up against statistical significance","volume":"567","author":"Amrhein","year":"2019","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100085","DOI":"10.1016\/j.gloepi.2022.100085","article-title":"P-value, compatibility, and S-value","volume":"4","author":"Mansournia","year":"2022","journal-title":"Glob. Epidemiol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Corfield, D., and Williamson, J. (2001). Foundations of Bayesianism, Springer Netherlands.","DOI":"10.1007\/978-94-017-1586-7"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07357907.2021.1999971","article-title":"Causal Considerations Can Inform the Interpretation of Surprising Associations in Medical Registries","volume":"40","author":"Gallego","year":"2022","journal-title":"Cancer Investig."},{"key":"ref_43","unstructured":"Bareinboim, E., Correa, J.D., Ibeling, D., and Icard, T.F. (2022). Probabilistic and Causal Inference: The Works of Judea Pearl, ACM Books."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1145\/3501714.3501747","article-title":"The Causal Foundations of Applied Probability and Statistics","volume":"Volume 36","author":"Greenland","year":"2022","journal-title":"Probabilistic and Causal Inference: The Works of Judea Pearl"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Junk, T.R., and Lyons, L. (2020). Reproducibility and Replication of Experimental Particle Physics Results. arXiv.","DOI":"10.1162\/99608f92.250f995b"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: Results of CALGB 90202 (alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3758\/s13423-015-0947-8","article-title":"The fallacy of placing confidence in confidence intervals","volume":"23","author":"Morey","year":"2016","journal-title":"Psychon. Bull. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1080\/00031305.2018.1543137","article-title":"Inferential Statistics as Descriptive Statistics: There Is No Replication Crisis if We Don\u2019t Expect Replication","volume":"73","author":"Amrhein","year":"2019","journal-title":"Am. Stat."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/00031305.2018.1529625","article-title":"Valid P-Values Behave Exactly as They Should: Some Misleading Criticisms of P-Values and Their Resolution With S-Values","volume":"73","author":"Greenland","year":"2019","journal-title":"Am. Stat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1080\/01621459.2000.10474264","article-title":"On the Probability of Observing Misleading Statistical Evidence","volume":"95","author":"Royall","year":"2000","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/insr.12000","article-title":"Confidence Distribution, the Frequentist Distribution Estimator of a Parameter: A Review","volume":"81","author":"Xie","year":"2013","journal-title":"Int. Stat. Rev."},{"key":"ref_52","first-page":"4","article-title":"Double Your Variance, Dirtify Your Bayes, Devour Your Pufferfish, and Draw your Kidstrogram","volume":"1","author":"Meng","year":"2022","journal-title":"N. Engl. J. Stat. Data Sci."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Efron, B., and Hastie, T. (2016). Computer Age Statistical Inference: Algorithms, Evidence, and Data Science, Cambridge University Press.","DOI":"10.1017\/CBO9781316576533"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2022.02.022","article-title":"Medicine before and after David Cox","volume":"98","author":"Msaouel","year":"2022","journal-title":"Eur. J. Intern. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/ije\/dyi312","article-title":"Bayesian perspectives for epidemiological research: I. Foundations and basic methods","volume":"35","author":"Greenland","year":"2006","journal-title":"Int. J. Epidemiol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Gelman, A., Hill, J., and Vehtari, A. (2020). Regression and Other Stories, Cambridge University Press.","DOI":"10.1017\/9781139161879"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/EDE.0b013e31818131e7","article-title":"Why most discovered true associations are inflated","volume":"19","author":"Ioannidis","year":"2008","journal-title":"Epidemiology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s10654-019-00552-z","article-title":"Multiple comparisons controversies are about context and costs, not frequentism versus Bayesianism","volume":"34","author":"Greenland","year":"2019","journal-title":"Eur. J. Epidemiol."},{"key":"ref_60","first-page":"42","article-title":"You May Believe You Are a Bayesian But You Are Probably Wrong","volume":"2","author":"Senn","year":"2011","journal-title":"Ration. Mark. Morals"},{"key":"ref_61","unstructured":"Strevens, M. (2020). The Knowledge Machine: How irrationality Created Modern Science, Liveright Publishing Corporation. [1st ed.]."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/07357907.2022.2136681","article-title":"Less is More? First Impressions From COSMIC-313","volume":"41","author":"Msaouel","year":"2023","journal-title":"Cancer Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"d2090","DOI":"10.1136\/bmj.d2090","article-title":"How to obtain the confidence interval from a P value","volume":"343","author":"Altman","year":"2011","journal-title":"BMJ"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1198\/000313001300339897","article-title":"The Abuse of Power","volume":"55","author":"Hoenig","year":"2001","journal-title":"Am. Stat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/07357907.2022.2084621","article-title":"The Big Data Paradox in Clinical Practice","volume":"40","author":"Msaouel","year":"2022","journal-title":"Cancer Investig."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Searle, S.R., Casella, G., and McCulloch, C.E. (1992). Variance Components, Wiley.","DOI":"10.1002\/9780470316856"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/ije\/29.1.158","article-title":"Principles of multilevel modelling","volume":"29","author":"Greenland","year":"2000","journal-title":"Int. J. Epidemiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-5573-6-4","article-title":"Identifiability, exchangeability and confounding revisited","volume":"6","author":"Greenland","year":"2009","journal-title":"Epidemiol. Perspect. Innov."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/oxfordjournals.aje.a112313","article-title":"Recent methodological contributions to clinical trials","volume":"104","author":"Cornfield","year":"1976","journal-title":"Am. J. Epidemiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1198\/000313006X106190","article-title":"The Boxer, the Wrestler, and the Coin Flip","volume":"60","author":"Gelman","year":"2006","journal-title":"Am. Stat."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1007\/s00024-022-03137-2","article-title":"Pay No Attention to the Model Behind the Curtain","volume":"179","author":"Stark","year":"2022","journal-title":"Pure Appl. Geophys."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10739-006-9119-z","article-title":"RA Fisher and his advocacy of randomization","volume":"40","author":"Hall","year":"2007","journal-title":"J. Hist. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1445-2197.1994.tb02308.x","article-title":"Issues in biomedical statistics: Statistical inference","volume":"64","author":"Ludbrook","year":"1994","journal-title":"Aust. N. Z. J. Surg."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Shapiro, D.D., and Msaouel, P. (2021). Causal Diagram Techniques for Urologic Oncology Research. Clin. Genitourin. Cancer, 19.","DOI":"10.1016\/j.clgc.2020.08.003"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/jama.2022.1816","article-title":"Causal Directed Acyclic Graphs","volume":"327","author":"Lipsky","year":"2022","journal-title":"JAMA"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00001648-199901000-00008","article-title":"Causal diagrams for epidemiologic research","volume":"10","author":"Greenland","year":"1999","journal-title":"Epidemiology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7345","DOI":"10.1073\/pnas.1510507113","article-title":"Causal inference and the data-fusion problem","volume":"113","author":"Bareinboim","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","first-page":"698","article-title":"Transportability of Causal Effects: Completeness Results","volume":"26","author":"Bareinboim","year":"2021","journal-title":"Proc. AAAI Conf. Artif. Intell."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/07357907.2021.1974030","article-title":"Impervious to Randomness: Confounding and Selection Biases in Randomized Clinical Trials","volume":"39","author":"Msaouel","year":"2021","journal-title":"Cancer Investig."},{"key":"ref_83","unstructured":"Correa, J., Tian, J., and Bareinboim, E. (2019, January 9\u201315). Adjustment criteria for generalizing experimental findings. Proceedings of the International Conference on Machine Learning, Long Beach, CA, USA."},{"key":"ref_84","unstructured":"Bareinboim, E., and Pearl, J. (2012, January 21\u201323). Controlling Selection Bias in Causal Inference. Proceedings of the Fifteenth International Conference on Artificial Intelligence and Statistics, Proceedings of Machine Learning Research, La Palma, Canary Islands, Spain."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","article-title":"A structural approach to selection bias","volume":"15","author":"Hernan","year":"2004","journal-title":"Epidemiology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/EDE.0000000000001516","article-title":"Toward a Clearer Definition of Selection Bias When Estimating Causal Effects","volume":"33","author":"Lu","year":"2022","journal-title":"Epidemiology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00001648-199011000-00003","article-title":"Randomization, statistics, and causal inference","volume":"1","author":"Greenland","year":"1990","journal-title":"Epidemiology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/sim.4780091108","article-title":"The graphical representation of clinical trials with particular reference to measurements over time","volume":"9","author":"Senn","year":"1990","journal-title":"Stat. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1002\/sim.2074","article-title":"Controversies concerning randomization and additivity in clinical trials","volume":"23","author":"Senn","year":"2004","journal-title":"Stat. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.eururo.2021.10.001","article-title":"First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial","volume":"81","author":"Albiges","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_92","unstructured":"R Core Team (2018). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.eururo.2022.09.014","article-title":"Methods Modernizing Statistical Reporting in Medical Journals: Challenges and Future Directions","volume":"82","author":"Vickers","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","article-title":"Survival plots of time-to-event outcomes in clinical trials: Good practice and pitfalls","volume":"359","author":"Pocock","year":"2002","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"Laupacis","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/1467-985X.00175","article-title":"Number needed to treat: Properties and problems","volume":"163","author":"Hutton","year":"2000","journal-title":"J. R. Stat. Soc. Ser. A Stat. Soc."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF03256810","article-title":"Misleading Statistics","volume":"24","author":"Hutton","year":"2010","journal-title":"Pharm. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1002\/sim.6739","article-title":"Mastering variation: Variance components and personalised medicine","volume":"35","author":"Senn","year":"2016","journal-title":"Stat. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/sim.4780131703","article-title":"Testing for baseline balance in clinical trials","volume":"13","author":"Senn","year":"1994","journal-title":"Stat. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1002\/sim.5713","article-title":"Seven myths of randomisation in clinical trials","volume":"32","author":"Senn","year":"2013","journal-title":"Stat. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.2106\/JBJS.21.01166","article-title":"The Table I Fallacy: P Values in Baseline Tables of Randomized Controlled Trials","volume":"104","author":"Pijls","year":"2022","journal-title":"J. Bone Joint. Surg. Am."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-soc-071913-043455","article-title":"Endogenous Selection Bias: The Problem of Conditioning on a Collider Variable","volume":"40","author":"Elwert","year":"2014","journal-title":"Annu. Rev. Sociol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2307\/2529712","article-title":"Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial","volume":"31","author":"Pocock","year":"1975","journal-title":"Biometrics"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/cpt1974155443","article-title":"Minimization: A new method of assigning patients to treatment and control groups","volume":"15","author":"Taves","year":"1974","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1541-0420.2010.01545.x","article-title":"Minimize the use of minimization with unequal allocation","volume":"67","author":"Proschan","year":"2011","journal-title":"Biometrics"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1038\/bjc.2011.157","article-title":"Statistical issues in the use of dynamic allocation methods for balancing baseline covariates","volume":"104","author":"Pond","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/10543400802527908","article-title":"Permutation test following covariate-adaptive randomization in randomized controlled trials","volume":"19","author":"Hasegawa","year":"2009","journal-title":"J. Biopharm. Stat."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Friedman, L.M., DeMets, D.L., Furberg, C.D., Granger, C.B., and Reboussin, D.M. (2015). Fundamentals of Clinical Trials, Springer.","DOI":"10.1007\/978-3-319-18539-2"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/00031305.1991.10475813","article-title":"On the Logical Justification of Conditional Tests for Two-By-Two Contingency Tables","volume":"45","author":"Greenland","year":"1991","journal-title":"Am. Stat."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1001\/jama.2022.21506","article-title":"Adjustment for Baseline Characteristics in Randomized Clinical Trials","volume":"328","author":"Holmberg","year":"2022","journal-title":"JAMA"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Harrell, J.F.E. (2015). Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis, Springer.","DOI":"10.1007\/978-3-319-19425-7"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Greenland, S., Pearl, J., and Robins, J.M. (1999). Confounding and Collapsibility in Causal Inference. Stat. Sci., 14.","DOI":"10.1214\/ss\/1009211805"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1136\/jech.2002.006361","article-title":"A definition of causal effect for epidemiological research","volume":"58","author":"Hernan","year":"2004","journal-title":"J. Epidemiol. Community Health"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/01621459.1986.10478354","article-title":"Statistics and Causal Inference","volume":"81","author":"Holland","year":"1986","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/aristotelian\/13.1.1","article-title":"On the notion of cause","volume":"Volume 13","author":"Russell","year":"1912","journal-title":"Proceedings of the Aristotelian Society"},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Gelman, A., and Imbens, G. (2013). Why Ask Why? Forward Causal Inference and Reverse Causal Questions, National Bureau of Economic Research.","DOI":"10.3386\/w19614"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1198\/016214504000001880","article-title":"Causal Inference Using Potential Outcomes","volume":"100","author":"Rubin","year":"2005","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/EDE.0000000000000939","article-title":"Note on \u201cGeneralizability of Study Results\u201d","volume":"30","author":"Pearl","year":"2019","journal-title":"Epidemiology"},{"key":"ref_120","unstructured":"Brooks, D. (2012). The Sampling Distribution and Central Limit Theorem, CreateSpace Independent Publishing Platform."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1146\/annurev-statistics-042522-103837","article-title":"A Review of Generalizability and Transportability","volume":"10","author":"Degtiar","year":"2023","journal-title":"Annu. Rev. Stat. Its Appl."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/sim.8426","article-title":"Extending inferences from a randomized trial to a new target population","volume":"39","author":"Dahabreh","year":"2020","journal-title":"Stat. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10654-019-00533-2","article-title":"Extending inferences from a randomized trial to a target population","volume":"34","author":"Dahabreh","year":"2019","journal-title":"Eur. J. Epidemiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1037\/h0040950","article-title":"Factors relevant to the validity of experiments in social settings","volume":"54","author":"Campbell","year":"1957","journal-title":"Psychol. Bull."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-polisci-041719-102556","article-title":"External Validity","volume":"24","author":"Findley","year":"2021","journal-title":"Annu. Rev. Political Sci."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/ije\/dys223","article-title":"Why representativeness should be avoided","volume":"42","author":"Rothman","year":"2013","journal-title":"Int. J. Epidemiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/ije\/dyt103","article-title":"Commentary: Representativeness is usually not necessary and often should be avoided","volume":"42","author":"Richiardi","year":"2013","journal-title":"Int. J. Epidemiol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/ije\/dyt105","article-title":"Commentary: Should we always deliberately be non-representative?","volume":"42","author":"Ebrahim","year":"2013","journal-title":"Int. J. Epidemiol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/ije\/dyt124","article-title":"Rebuttal: When it comes to scientific inference, sometimes a cigar is just a cigar","volume":"42","author":"Rothman","year":"2013","journal-title":"Int. J. Epidemiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jclinepi.2020.05.001","article-title":"Treatment effects may remain the same even when trial participants differed from the target population","volume":"124","author":"Bradburn","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jclinepi.2003.08.009","article-title":"Subgroup analyses in randomized trials: Risks of subgroup-specific analyses; power and sample size for the interaction test","volume":"57","author":"Brookes","year":"2004","journal-title":"J. Clin. Epidemiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.amepre.2015.07.036","article-title":"Enrolling Minority and Underserved Populations in Cancer Clinical Research","volume":"50","author":"Wallington","year":"2016","journal-title":"Am. J. Prev. Med."},{"key":"ref_133","first-page":"226","article-title":"Barriers and facilitators to participation of minorities in clinical trials","volume":"22","author":"Schmotzer","year":"2012","journal-title":"Ethn. Dis."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1002\/cncr.32495","article-title":"Inclusiveness and ethical considerations for observational, translational, and clinical cancer health disparity research","volume":"125","author":"Behring","year":"2019","journal-title":"Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jspi.2011.07.008","article-title":"Estimation of an indicator of the representativeness of survey response","volume":"142","author":"Shlomo","year":"2012","journal-title":"J. Stat. Plan. Inference"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e005791","DOI":"10.1136\/bmjopen-2014-005791","article-title":"Random sample community-based health surveys: Does the effort to reach participants matter?","volume":"4","author":"Messiah","year":"2014","journal-title":"BMJ Open"},{"key":"ref_137","first-page":"1","article-title":"Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers","volume":"42","author":"Apolo","year":"2022","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev-statistics-010814-020310","article-title":"There Is Individualized Treatment. Why Not Individualized Inference?","volume":"3","author":"Liu","year":"2016","journal-title":"Annu. Rev. Stat. Its Appl."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1002\/sim.9120","article-title":"Precision Bayesian phase I-II dose-finding based on utilities tailored to prognostic subgroups","volume":"40","author":"Lee","year":"2021","journal-title":"Stat. Med."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/nrc.2017.32","article-title":"Common pitfalls in preclinical cancer target validation","volume":"17","author":"Kaelin","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1353\/obs.2022.0009","article-title":"Interview with Don Rubin","volume":"8","author":"Rubin","year":"2022","journal-title":"Obs. Stud."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1093\/ije\/dyx275","article-title":"An introduction to instrumental variables for epidemiologists","volume":"47","author":"Greenland","year":"2018","journal-title":"Int. J. Epidemiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/EDE.0000000000000564","article-title":"Biases in Randomized Trials: A Conversation Between Trialists and Epidemiologists","volume":"28","author":"Mansournia","year":"2017","journal-title":"Epidemiology"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2208375","article-title":"Effect of Colonoscopy Screening on Risks of Colorectal Cancer and Related Death","volume":"387","author":"Bretthauer","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/EDE.0000000000001234","article-title":"Defining and Identifying Per-protocol Effects in Randomized Trials","volume":"31","author":"Rudolph","year":"2020","journal-title":"Epidemiology"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"35","DOI":"10.7326\/M18-3667","article-title":"The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement","volume":"172","author":"Kent","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_147","unstructured":"Greenland, S. (2014). Wiley StatsRef: Statistics Reference Online, Wiley Online Library."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"pky006","DOI":"10.1093\/jncics\/pky006","article-title":"Prognosis vs. Treatment Interaction","volume":"2","author":"Cuzick","year":"2018","journal-title":"JNCI Cancer Spectr."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: Correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/12.suppl_1.S23","article-title":"HER2 as a prognostic and predictive marker for breast cancer","volume":"12","author":"Cooke","year":"2001","journal-title":"Ann. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMcibr1909386","article-title":"HER2 and Breast Cancer\u2014A Phenomenal Success Story","volume":"381","author":"Hayes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1080\/10543406.2017.1379532","article-title":"On Enrichment Strategies for Biomarker Stratified Clinical Trials","volume":"28","author":"Wang","year":"2018","journal-title":"J. Biopharm. Stat."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev-statistics-040720-032818","article-title":"Adaptive Enrichment Designs in Clinical Trials","volume":"8","author":"Thall","year":"2021","journal-title":"Annu. Rev. Stat. Appl."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/biom.13421","article-title":"Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers","volume":"78","author":"Park","year":"2022","journal-title":"Biometrics"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"17588359221103199","DOI":"10.1177\/17588359221103199","article-title":"Missing the trees for the forest: Most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive","volume":"14","author":"Hahn","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJMe1906559","article-title":"New Guidelines for Statistical Reporting in the Journal","volume":"381","author":"Harrington","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"k4245","DOI":"10.1136\/bmj.k4245","article-title":"Personalized evidence based medicine: Predictive approaches to heterogeneous treatment effects","volume":"363","author":"Kent","year":"2018","journal-title":"BMJ"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability","volume":"15","author":"Schuirmann","year":"1987","journal-title":"J. Pharmacokinet. Biopharm."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41409-019-0679-x","article-title":"Cubic splines to model relationships between continuous variables and outcomes: A guide for clinicians","volume":"55","author":"Gauthier","year":"2020","journal-title":"Bone Marrow Transpl."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1200\/JCO.2015.66.1595","article-title":"Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance)","volume":"34","author":"Dickler","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): A phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S0140-6736(05)61026-4","article-title":"Forest plots and the interpretation of subgroups","volume":"365","author":"Cuzick","year":"2005","journal-title":"Lancet"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","unstructured":"Blume, J.D., D\u2019Agostino McGowan, L., Dupont, W.D., and Greevy, R.A.J. (2018). Second-generation p-values: Improved rigor, reproducibility, & transparency in statistical analyses. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0188299"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/jama.2018.19192","article-title":"Challenges of Non-Intention-to-Treat Analyses","volume":"321","author":"DeMets","year":"2019","journal-title":"JAMA"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1056\/NEJMra1510063","article-title":"Challenges in the Design and Interpretation of Noninferiority Trials","volume":"377","author":"Mauri","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jclinepi.2015.11.009","article-title":"Noninferiority is (too) common in noninferiority trials","volume":"71","author":"Soonawala","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jclinepi.2015.11.010","article-title":"Noninferiority is almost certain with lenient noninferiority margins","volume":"71","author":"Flacco","year":"2016","journal-title":"J. Clin. Epidemiol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1164\/rccm.202006-2381CP","article-title":"Using Bayesian Methods to Augment the Interpretation of Critical Care Trials. An Overview of Theory and Example Reanalysis of the Alveolar Recruitment for Acute Respiratory Distress Syndrome Trial","volume":"203","author":"Zampieri","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2307\/2983527","article-title":"Bayesian Approaches to Randomized Trials","volume":"157","author":"Spiegelhalter","year":"1994","journal-title":"J. R. Stat. Soc. Ser. A Stat. Soc."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41573-023-00638-0","article-title":"Application of Bayesian approaches in drug development: Starting a virtuous cycle","volume":"22","author":"Ruberg","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1056\/NEJMoa1800385","article-title":"Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome","volume":"378","author":"Combes","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1056\/NEJMe1805123","article-title":"Learning from a Trial Stopped by a Data and Safety Monitoring Board","volume":"378","author":"Harrington","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2018.14276","article-title":"Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome and Posterior Probability of Mortality Benefit in a Post Hoc Bayesian Analysis of a Randomized Clinical Trial","volume":"320","author":"Goligher","year":"2018","journal-title":"JAMA"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/pst.2219","article-title":"Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments","volume":"21","author":"Weir","year":"2022","journal-title":"Pharm. Stat."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/19466315.2022.2081601","article-title":"Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation","volume":"15","author":"Ionan","year":"2022","journal-title":"Stat. Biopharm. Res."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/19466315.2023.2173645","article-title":"What Can Be Achieved with the Estimand Framework?","volume":"15","author":"Mayo","year":"2023","journal-title":"Stat. Biopharm. Res."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1200\/JCO.2011.34.6056","article-title":"Overall survival as the outcome for randomized clinical trials with effective subsequent therapies","volume":"29","author":"Korn","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2012.44.1220","article-title":"Before we throw out progression-free survival as a valid end point","volume":"30","author":"Stewart","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: Meaningful or simply measurable?","volume":"30","author":"Booth","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.leu.2405016","article-title":"Clinically relevant end points and new drug approvals for myeloma","volume":"22","author":"Anderson","year":"2008","journal-title":"Leukemia"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1200\/JCO.2008.19.9810","article-title":"Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: Data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916","volume":"27","author":"Hussain","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1016\/S2352-3026(19)30023-7","article-title":"Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: An open-label, randomised, phase 3 trial","volume":"6","author":"Bashir","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/(SICI)1097-0258(20000430)19:8<1011::AID-SIM414>3.0.CO;2-M","article-title":"Evaluating multiple treatment courses in clinical trials","volume":"19","author":"Thall","year":"2000","journal-title":"Stat. Med."},{"key":"ref_188","doi-asserted-by":"crossref","unstructured":"Chakraborty, B., and Moodie, E.E.M. (2013). Statistical Methods for Dynamic Treatment Regimes: Reinforcement Learning, Causal Inference, and Personalized Medicine, Springer.","DOI":"10.1007\/978-1-4614-7428-9"},{"key":"ref_189","doi-asserted-by":"crossref","unstructured":"Tsiatis, A.A. (2020). Dynamic Treatment Regimes: Statistical Methods for Precision Medicine, Taylor & Francis Group.","DOI":"10.1201\/9780429192692"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2105\/AJPH.2022.307135","article-title":"The Sequential Multiple Assignment Randomized Trial for Controlling Infectious Diseases: A Review of Recent Developments","volume":"113","author":"Wang","year":"2023","journal-title":"Am. J. Public Health"},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1002\/sim.2022","article-title":"An experimental design for the development of adaptive treatment strategies","volume":"24","author":"Murphy","year":"2005","journal-title":"Stat. Med."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/01621459.2012.665615","article-title":"SMART Design Issues and the Consideration of Opposing Outcomes: Discussion of \u201cEvaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer\u201d by Wang, Rotnitzky, Lin, Millikan, and Thall","volume":"107","author":"Almirall","year":"2012","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s13142-014-0265-0","article-title":"Introduction to SMART designs for the development of adaptive interventions: With application to weight loss research","volume":"4","author":"Almirall","year":"2014","journal-title":"Transl. Behav. Med."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-statistics-022513-115553","article-title":"Dynamic Treatment Regimes","volume":"1","author":"Chakraborty","year":"2014","journal-title":"Annu. Rev. Stat. Appl."},{"key":"ref_196","doi-asserted-by":"crossref","unstructured":"Boele, F., Harley, C., Pini, S., Kenyon, L., Daffu-O\u2019Reilly, A., and Velikova, G. (2019). Cancer as a chronic illness: Support needs and experiences. BMJ Support. Palliat. Care.","DOI":"10.1136\/bmjspcare-2019-001882"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/01621459.2011.641416","article-title":"Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer","volume":"107","author":"Wang","year":"2012","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1467-9876.2012.01048.x","article-title":"Evaluating Joint Effects of Induction-Salvage Treatment Regimes on Overall Survival in Acute Leukemia","volume":"62","author":"Wahed","year":"2013","journal-title":"J. R. Stat. Soc. Ser. C Appl. Stat."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1002\/sim.6558","article-title":"Optimization of multi-stage dynamic treatment regimes utilizing accumulated data","volume":"34","author":"Huang","year":"2015","journal-title":"Stat. Med."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1080\/01621459.2015.1086353","article-title":"Bayesian Nonparametric Estimation for Dynamic Treatment Regimes with Sequential Transition Times","volume":"111","author":"Xu","year":"2016","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1002\/pst.1819","article-title":"Bayesian nonparametric statistics: A new toolkit for discovery in cancer research","volume":"16","author":"Thall","year":"2017","journal-title":"Pharm. Stat."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1080\/01621459.2017.1340887","article-title":"A Bayesian Machine Learning Approach for Optimizing Dynamic Treatment Regimes","volume":"113","author":"Murray","year":"2018","journal-title":"J. Am. Stat. Assoc."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/07357907.2021.2020281","article-title":"Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit","volume":"40","author":"Valenti","year":"2022","journal-title":"Cancer Investig."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jval.2017.09.010","article-title":"Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany","volume":"21","author":"Isbary","year":"2018","journal-title":"Value Health"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: An open-label phase 1b and randomised phase 2 trial","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients with Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial","volume":"323","author":"Tap","year":"2020","journal-title":"JAMA"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years","volume":"375","author":"Goss","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1177\/0962280217708661","article-title":"Dynamic treatment regimes, past, present, and future: A conversation with experts","volume":"26","author":"Laber","year":"2017","journal-title":"Stat. Methods Med. Res."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/2159-8290.CD-21-0212","article-title":"Independent Drug Action in Combination Therapy: Implications for Precision Oncology","volume":"12","author":"Plana","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.tibtech.2012.12.006","article-title":"Combination approaches to combat multidrug-resistant bacteria","volume":"31","author":"Worthington","year":"2013","journal-title":"Trends Biotechnol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/35073673","article-title":"HIV chemotherapy","volume":"410","author":"Richman","year":"2001","journal-title":"Nature"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1128\/CMR.05041-11","article-title":"Combination therapy for treatment of infections with gram-negative bacteria","volume":"25","author":"Tamma","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/mBio.01586-16","article-title":"Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application","volume":"8","author":"Kerantzas","year":"2017","journal-title":"mBio"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V13.12.1126.1126","article-title":"A comparative study of two regimens of combination chemotherapy in acute leukemia","volume":"13","author":"Frei","year":"1958","journal-title":"Blood"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"eabm6420","DOI":"10.1126\/scitranslmed.abm6420","article-title":"A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy","volume":"14","author":"Msaouel","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/sim.8528","article-title":"A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and death","volume":"39","author":"Lee","year":"2020","journal-title":"Stat. Med."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Yuan, Y., Nguyen, H.Q., and Thall, P.F. (2017). Bayesian Designs for Phase I-II Clinical Trials, CRC Press.","DOI":"10.1201\/b21600"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: Clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"Couriel","year":"2004","journal-title":"Blood"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/biom.13433","article-title":"Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics","volume":"78","author":"Gerard","year":"2022","journal-title":"Biometrics"},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Montgomery, A.A., Peters, T.J., and Little, P. (2003). Design, analysis and presentation of factorial randomised controlled trials. BMC Med. Res. Methodol., 3.","DOI":"10.1186\/1471-2288-3-26"},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"e004059","DOI":"10.1136\/jitc-2021-004059","article-title":"In silico modeling of combination systemic therapy for advanced renal cell carcinoma","volume":"9","author":"Kotecha","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood.V18.4.431.431","article-title":"Studies of sequential and combination antimetabolite therapy in acute leukemia: 6-mercaptopurine and methotrexate","volume":"18","author":"Frei","year":"1961","journal-title":"Blood"},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/2159-8290.CD-12-0460","article-title":"Molecular classification of prostate cancer progression: Foundation for marker-driven treatment of prostate cancer","volume":"3","author":"Logothetis","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2307\/3314804","article-title":"Mixture Models in Survival Analysis: Are They Worth the Risk?","volume":"14","author":"Farewell","year":"1986","journal-title":"Can. J. Stat.\/La Rev. Can. Stat."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-statistics-031017-100101","article-title":"Cure Models in Survival Analysis","volume":"5","author":"Amico","year":"2018","journal-title":"Annu. Rev. Stat. Its Appl."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/sim.4780101106","article-title":"Falsificationism and clinical trials","volume":"10","author":"Senn","year":"1991","journal-title":"Stat. Med."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/ije\/dyab157","article-title":"Causal diagrams for immortal time bias","volume":"50","author":"Mansournia","year":"2021","journal-title":"Int. J. Epidemiol."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","article-title":"Challenges of guarantee-time bias","volume":"31","author":"Gelber","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/pst.322","article-title":"Lessons from TGN1412 and TARGET: Implications for observational studies and meta-analysis","volume":"7","author":"Senn","year":"2008","journal-title":"Pharm. Stat."},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1740-9713.2012.00620.x","article-title":"Tea for three: Of infusions and inferences and milk in first","volume":"9","author":"Senn","year":"2012","journal-title":"Significance"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1214\/ss\/1056397489","article-title":"A Conversation with John Nelder","volume":"18","author":"Senn","year":"2003","journal-title":"Stat. Sci."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s10654-015-9995-7","article-title":"Limitations of individual causal models, causal graphs, and ignorability assumptions, as illustrated by random confounding and design unfaithfulness","volume":"30","author":"Greenland","year":"2015","journal-title":"Eur. J. Epidemiol."},{"key":"ref_235","first-page":"55","article-title":"Confounding and effect modification: Distribution and measure","volume":"1","author":"Weele","year":"2012","journal-title":"Epidemiol. Methods"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2188\/jea.JE20190192","article-title":"Causal Diagrams: Pitfalls and Tips","volume":"30","author":"Suzuki","year":"2020","journal-title":"J. Epidemiol."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/EDE.0000000000000797","article-title":"A Practical Example Demonstrating the Utility of Single-world Intervention Graphs","volume":"29","author":"Breskin","year":"2018","journal-title":"Epidemiology"},{"key":"ref_238","unstructured":"Richardson, T.S., and Robins, J.M. (2013). Second UAI Workshop on Causal Structure Learning, Bellevue."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1002\/sim.9833","article-title":"Single-world intervention graphs for defining, identifying, and communicating estimands in clinical trials","volume":"42","author":"Ocampo","year":"2023","journal-title":"Stat. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4674\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:55:38Z","timestamp":1760129738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/19\/4674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":239,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["cancers15194674"],"URL":"https:\/\/doi.org\/10.3390\/cancers15194674","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]}}}